Concord Drugs Limited Raises ₹18.88 Crore Through Preferential Allotment

Concord Drugs Limited (CDL) has successfully completed a significant capital raising initiative through a preferential allotment of equity shares and convertible warrants. The company's board of directors approved the allotment in a meeting held on November 20, 2025, marking a strategic move to bolster its financial position.

Equity Share Allotment

CDL has allotted 31,75,000 fully paid-up equity shares at an issue price of ₹36.30 per share, which includes a premium of ₹26.30 over the face value of ₹10. This allotment has raised a total of ₹11.53 crore for the company.

Convertible Warrants

In addition to the equity shares, the board also approved the allotment of 20,25,000 convertible warrants. Each warrant is convertible into one fully paid-up equity share of ₹10 face value, at an issue price of ₹36.30 per warrant. The total amount to be raised through these warrants is ₹7.35 crore.

Allotment Details

The preferential allotment was made to both promoters and public investors. Here's a breakdown of the allotment:

Category	Equity Shares	Convertible Warrants
Promoters	5,00,000	18,00,000
Public	26,75,000	2,25,000
Total	31,75,000	20,25,000

Key Points

The company has received 25% upfront consideration for the warrants from the allottees.
The warrants are convertible within 18 months from the date of allotment, subject to payment of the balance consideration.
This capital raise is pursuant to the approval of shareholders at the Extraordinary General Meeting held on July 31, 2025.
The allotment complies with SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018.

This preferential allotment represents a significant move for Concord Drugs Limited, potentially providing the company with additional capital for its growth initiatives.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.24%	-6.08%	+27.39%	+151.62%	+127.62%	+238.96%

Concord Drugs Limited , a pharmaceutical company based in Telangana, has announced its unaudited financial results for the second quarter and half-year ended September 30, 2025. The company's performance shows a mixed picture, with improvements in some areas and challenges in others.

Financial Highlights

Particulars	Standalone (H1 FY2026)	Consolidated (H1 FY2026)
Net Sales	Rs 2,345.63 crore	Rs 2,388.25 crore
Total Revenue	Rs 2,345.87 crore	Rs 2,388.49 crore
Profit Before Tax	Rs 42.11 crore	Rs 42.96 crore
Profit After Tax	Rs 30.53 crore	Rs 31.00 crore
Earnings Per Share (Basic)	Rs 0.31	Rs 0.31

Key Observations

Revenue and Profitability

The company's consolidated net sales for the half-year stood at Rs 2,388.25 crore, showing a slight increase over the standalone figure of Rs 2,345.63 crore.
Concord Drugs reported a consolidated profit after tax of Rs 31.00 crore for the half-year, marginally higher than the standalone profit of Rs 30.53 crore.
Both standalone and consolidated earnings per share remained consistent at Rs 0.31 for the half-year period.

Balance Sheet Position

As of September 30, 2025, the company's consolidated total assets stood at Rs 6,861.30 crore, up from Rs 6,514.18 crore as of March 31, 2025.
The total equity increased to Rs 3,441.89 crore from Rs 3,411.36 crore in the previous fiscal year-end.

Management Commentary

The Board of Directors, in their meeting held on November 13, 2025, approved these unaudited financial results. The results were reviewed by the Audit Committee and audited by Pundarikashyam and Associates, Chartered Accountants.

Investor Information

The company has stated that the financial results are available on its website ( https://concorddrugs.in/investor-relations ) and on the BSE Ltd. website ( www.bseindia.com ). The results will also be published in newspapers as per regulatory requirements.